Table 2.
Multivariate linear regression models for glycated haemoglobin (HbA1c) at 6 mo of metformin treatment, before and after addition of genetic risk scores (adjusted for HbA1c at baseline)
| Variable | Imputed (N = 282) | |||||
|---|---|---|---|---|---|---|
| Without GRS | IS‐GRS | Total GRS | ||||
| β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | |
| Female gender | 0.47 (−0.90; 1.85) | .500 | 0.48 (−0.90; 1.85) | .497 | 0.46 (−0.92; 1.84) | .512 |
| Age (y) | −0.04 (−0.12; 0.04) | .288 | −0.04 (−0.12; 0.04) | .306 | −0.04 (−0.12; 0.04) | .333 |
| Diabetes duration | ||||||
| 0‐3 mo | 0.00 | 0.00 | 0.00 | |||
| >3 mo | 2.69 (1.31; 4.07) | <.001 | 2.69 (1.30; 4.06) | <.001 | 2.70 (1.32; 4.08) | <.001 |
| HbA1c control status | ||||||
| <53 mmol/mol | 0.00 | |||||
| ≥53 mmol/mol | 3.08 (1.18; 4.98) | .002 | 3.09 (1.18; 4.99) | .002 | 3.09 (1.19; 4.99) | .002 |
| IS‐GRS/total GRS | ‐ | ‐ | 0.05 (−0.45; 0.55) | .849 | 0.04 (−0.09; 0.15) | .586 |
| R2 | 0.22 | 0.22 | 0.22 | |||
| Variable | Complete case (N = 227) | |||||
|---|---|---|---|---|---|---|
| Without GRS | IS‐GRS | Total GRS | ||||
| β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | |
| Female gender | 0.49 (−0.87; 1.85) | .475 | 0.49 (−0.87; 1.86) | .476 | 0.49 (−0.87; 1.85) | .481 |
| Age (y) | −0.03 (−0.10; 0.05) | .496 | −0.03 (−0.11; 0.05) | .490 | −0.02 (−0.10; 0.05) | .556 |
| Diabetes duration | ||||||
| 0‐3 mo | 0.00 | 0.00 | 0.00 | |||
| >3 mo | 2.59 (1.21; 3.97) | <.001 | 2.59 (1.20; 3.97) | <.001 | 2.60 (1.21; 3.98) | <.001 |
| HbA1c control status | ||||||
| <53 mmol/mol | 0.00 | |||||
| ≥53 mmol/mol | 3.57 (1.85; 5.28) | <.001 | 3.56 (1.84; 5.28) | <.001 | 3.58 (1.86; 5.30) | <.001 |
| IS‐GRS/total GRS | ‐ | ‐ | −0.03 (−0.54; 0.48) | .903 | 0.04 (−0.08; 0.16) | .542 |
| R2 | 0.24 | 0.24 | 0.24 | |||
Abbreviations: CI, confidence interval; GRS, genetic risk score; HbA1c, glycated haemoglobin; IS‐GRS, insulin sensitivity GRS.